DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
First-generation GLP-1 receptor agonist; active ingredient in Saxenda and Victoza.
Liraglutide is a GLP-1 receptor agonist with a 13-hour half-life, requiring daily subcutaneous dosing. Approved for type 2 diabetes (Victoza 2010) and chronic weight management (Saxenda 2014, the first FDA-approved GLP-1 for weight loss). Notable for being the only GLP-1 with an FDA indication for adolescents aged 12 and older (Saxenda).